Expression and Purification of Orphan Cytochrome P450 4X1 and Oxidation of Anandamide

Overview

Journal FEBS J

Specialty Biochemistry

Date 2008 Jun 14

PMID 18549450

Citations 47

Authors

Katarina Stark

Miroslav Dostalek

F P Guengerich

Affiliations

Soon will be listed here.

Abstract

Cytochrome P450 (P450) 4X1 is one of the so-called 'orphan' P450s without an assigned biological function. Codon-optimized P450 4X1 and a number of N-terminal modified sequences were expressed in Escherichia coli. Native P450 4X1 showed a characteristic P450 spectrum but low expression in E. coli DH5alpha cells (< 100 nmol P450.L(-1)). The highest level of expression (300-450 nmol P450.L(-1) culture) was achieved with a bicistronic P450 4X1 construct (N-terminal MAKKTSSKGKL, change of E2A, amino acids 3-44 truncated). Anandamide (arachidonoyl ethanolamide) has emerged as an important signaling molecule in the neurovascular cascade. Recombinant P450 4X1 protein, co-expressed with human NADPH-P450 reductase in E. coli, was found to convert the natural endocannabinoid anandamide to a single monooxygenated product, 14,15-epoxyeicosatrienoic (EET) ethanolamide. A stable anandamide analog (CD-25) was also converted to a monooxygenated product. Arachidonic acid was oxidized more slowly to 14,15- and 8,9-EETs but only in the presence of cytochrome b(5). Other fatty acids were investigated as putative substrates but showed only little or minor oxidation. Real-time PCR analysis demonstrated extrahepatic mRNA expression, including several human brain structures (cerebellum, amygdala and basal ganglia), in addition to expression in human heart, liver, prostate and breast. The highest mRNA expression levels were detected in amygdala and skin. The ability of P450 4X1 to generate anandamide derivatives and the mRNA distribution pattern suggest a potential role for P450 4X1 in anandamide signaling in the brain.

Citing Articles

Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism.

Guengerich F Pharmacol Rev. 2024; 76(6):1104-1132.

PMID: 39054072 PMC: 11549934. DOI: 10.1124/pharmrev.124.001173.

The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): An RNA sequence database analysis and review.

Leahy C, Osborne N, Shirota L, Rote P, Lee Y, Song B Biochem Pharmacol. 2024; 228:116241.

PMID: 38697309 PMC: 11774579. DOI: 10.1016/j.bcp.2024.116241.

Ninety-eight semesters of cytochrome P450 enzymes and related topics-What have I taught and learned?.

Guengerich F J Biol Chem. 2024; 300(2):105625.

PMID: 38185246 PMC: 10847173. DOI: 10.1016/j.jbc.2024.105625.

Heterologous Expression of Recombinant Human Cytochrome P450 (CYP) in : N-Terminal Modification, Expression, Isolation, Purification, and Reconstitution.

Shang T, Fang C, Ong C, Pan Y BioTech (Basel). 2023; 12(1).

PMID: 36810444 PMC: 9944785. DOI: 10.3390/biotech12010017.

Synthesis and Significance of Arachidonic Acid, a Substrate for Cyclooxygenases, Lipoxygenases, and Cytochrome P450 Pathways in the Tumorigenesis of Glioblastoma Multiforme, Including a Pan-Cancer Comparative Analysis.

Korbecki J, Rebacz-Maron E, Kupnicka P, Chlubek D, Baranowska-Bosiacka I Cancers (Basel). 2023; 15(3).

PMID: 36765904 PMC: 9913267. DOI: 10.3390/cancers15030946.

References

Fowler C . The pharmacology of the cannabinoid system--a question of efficacy and selectivity. Mol Neurobiol. 2007; 36(1):15-25. DOI: 10.1007/s12035-007-0001-6. View

Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman J . Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch Biochem Biophys. 2005; 436(1):50-61. DOI: 10.1016/j.abb.2005.02.001. View

Savas U, Hsu M, Griffin K, Bell D, Johnson E . Conditional regulation of the human CYP4X1 and CYP4Z1 genes. Arch Biochem Biophys. 2005; 436(2):377-85. DOI: 10.1016/j.abb.2005.02.022. View

Parikh A, Gillam E, Guengerich F . Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat Biotechnol. 1997; 15(8):784-8. DOI: 10.1038/nbt0897-784. View

Bylund J, Zhang C, Harder D . Identification of a novel cytochrome P450, CYP4X1, with unique localization specific to the brain. Biochem Biophys Res Commun. 2002; 296(3):677-84. DOI: 10.1016/s0006-291x(02)00918-x. View

Palmer S, Khanolkar A, Makriyannis A . Natural and synthetic endocannabinoids and their structure-activity relationships. Curr Pharm Des. 2000; 6(13):1381-97. DOI: 10.2174/1381612003399419. View

Kozak K, Marnett L . Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids. 2002; 66(2-3):211-20. DOI: 10.1054/plef.2001.0359. View

Felder C, Nielsen A, Briley E, Palkovits M, Priller J, Axelrod J . Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 1996; 393(2-3):231-5. DOI: 10.1016/0014-5793(96)00891-5. View

Sandhu P, Baba T, Guengerich F . Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Arch Biochem Biophys. 1993; 306(2):443-50. DOI: 10.1006/abbi.1993.1536. View

10.

Guengerich F . Oxidation-reduction properties of rat liver cytochromes P-450 and NADPH-cytochrome p-450 reductase related to catalysis in reconstituted systems. Biochemistry. 1983; 22(12):2811-20. DOI: 10.1021/bi00281a007. View

11.

Bornheim L, Kim K, Chen B, Correia M . Microsomal cytochrome P450-mediated liver and brain anandamide metabolism. Biochem Pharmacol. 1995; 50(5):677-86. DOI: 10.1016/0006-2952(95)00177-2. View

12.

Hanus L, Fride E, Breuer A, Vogel Z, Shalev D, Kustanovich I . 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A. 2001; 98(7):3662-5. PMC: 31108. DOI: 10.1073/pnas.061029898. View

13.

De Petrocellis L, Bisogno T, Maccarrone M, Davis J, Finazzi-Agro A, Di Marzo V . The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem. 2001; 276(16):12856-63. DOI: 10.1074/jbc.M008555200. View

14.

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

15.

Emoto C, Murase S, Sawada Y, Iwasaki K . In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A. Drug Metab Pharmacokinet. 2005; 20(5):351-7. DOI: 10.2133/dmpk.20.351. View

16.

Schenkman J, Remmer H, Estabrook R . Spectral studies of drug interaction with hepatic microsomal cytochrome. Mol Pharmacol. 1967; 3(2):113-23. View

17.

Herradon E, Martin M, Lopez-Miranda V . Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br J Pharmacol. 2007; 152(5):699-708. PMC: 2190007. DOI: 10.1038/sj.bjp.0707404. View

18.

Omura T, Sato R . THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem. 1964; 239:2370-8. View

19.

Costa B, Parolaro D, Colleoni M . Chronic treatment with the endocannabinoid anandamide increases cytochrome P450 metabolizing system in the rat. Eur J Pharmacol. 2002; 449(1-2):61-9. DOI: 10.1016/s0014-2999(02)01994-5. View

20.

Stark K, Guengerich F . Characterization of orphan human cytochromes P450. Drug Metab Rev. 2007; 39(2-3):627-37. DOI: 10.1080/03602530701467708. View